Prostate cancer – UK December 2009

© Cancer Research UK 2008 Registered charity number 1089464

Prostate cancer – UK

December 2009


Table One: Number of new cases and rates of prostate cancer, UK, 2006

England Wales Scotland N.Ireland UK

Cases

Males 30,024 2,164 2,506 821 35,515

Crude rate per 100,000 population

Males 120.5 149.8 101.5 96.2 119.6

Age-standardised rate (European) per 100,000 population

Males 98.1 108.2 81.6 92.1 97.195% CI 97.0 99.2 103.7 112.8 78.4 84.8 85.8 98.4 96.1 98.1


Figure One: Number of new cases and rates of prostate cancer, by age, UK, 2006


Figure Two: Age-standardised* incidence and mortality rates for prostate cancer by world regions, 2002 estimates

* to the European standard population


Figure Three: Age standardised* (European) incidence and mortality rates, prostate cancer in EU countries, 2006 estimates



Figure Four: Age standardised* (European) incidence and mortality rates, prostate cancer, males, GB, 1975-2007



Figure Five: Age-specific incidence rates, prostate cancer, Great Britain, 1975-2006


Figure Six: Age-standardised* rates of transurethral resection of the prostate (TURP) and crude rates of PSA testing, Scotland 1981-96



Figure Seven: Diagram of the prostate


Table Two: Treatment and management options for men with localised disease

(adapted with permission from NICE (2008) CG58. Prostate cancer: diagnosis and treatment. London.8

Low-risk men (PSA < 10ng/ml and Gleason score ≤6 and T1-T2a

Intermediate-risk men (PSA 10-20 ng/ml or Gleason score 7 or T2b-T2c

High-risk men (PSA >20 ng/ml or Gleason score 8-10 or T3-T4)

Watchful waiting ◊ ◊ ◊

Active surveillance ü ◊ X

Brachytherapy ◊ ◊ X

Prostatectomy ◊ ü ü*

High dose conformal radiotherapy ◊ ü† ü*†

Cryotherapy X* X* X*

High intensity focused ultrasound X* X* X*

ü Preferred treatment X Not recommended

◊ Treatment optionX* Not recommended unless as part of a clinical trial comparing use with established interventions

ü* Offer if there is a realistic prospect of †neo-adjuvant ± adjuvant hormone therapy (for Gleason score ≥8)

long term disease control is recommended


Figure Eight: Rates of radical prostatectomy and orchidectomy, England, 1991–2004(Adapted with permission from Hussain S et al. BJU Int 2008;101(5):547–55)


Figure Nine: Hormone treatment for prostate cancer, UK, 1975–2004(Adapted with permission from Hussain S et al. BJU Int 2008;101(5):547–55)


Figure Ten: One, five and ten-year age-standardised relative survival for prostate cancer, men aged 15-99 diagnosed in England and Wales, 1971–2001


Figure Eleven: Five-year age-adjusted relative survival, selected countries in Europe 1990-99 and the US, 1996-2003


Figure Twelve: Relative survival at five years since diagnosis by age, prostate cancer; patients diagnosed 1998-2001, England


Table Three: Number of deaths and mortality rates of prostate cancer, UK, 2007

England Wales Scotland N.Ireland UK

Deaths

Males 8,659 563 793 224 10,239

Crude rate per 100,000 population

Males 34.5 38.7 31.9 26.0 34.2

Age-standardised rate (European) per 100,000 population

Males 24.7 24.9 24.2 23.5 24.6

CI 95% 24.2 25.2 22.9 27.0 22.6 25.9 20.4 26.6 24.2 25.1


Figure Thirteen: Number of deaths and age-specific mortality rates, prostate cancer, UK, 2007


Figure Fourteen: Age-specific mortality rates, prostate cancer, UK, 1971-2007

Prostate cancer – UK December 2009

Documents